In preclinical studies on conditions like myocardial infarction, heart failure, and atherosclerosis, MCC950 showed impressive results by reducing IL-1β production, decreasing neutrophil infiltration, and limiting harmful cardiac remodeling. The gene discussed is IL1B; the disease is myocardial infarction.